<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-17584" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Angiotensin-Converting Enzyme Inhibitors (ACEI)</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Herman</surname>
            <given-names>Linda L.</given-names>
          </name>
          <aff>Kaweah Delta HCD Emergency Med Residency</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padala</surname>
            <given-names>Sandeep A.</given-names>
          </name>
          <aff>Augusta UMC/ Medical College of Georgia</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahmed</surname>
            <given-names>Intisar</given-names>
          </name>
          <aff>Aga Khan University Pakistan</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bashir</surname>
            <given-names>Khalid</given-names>
          </name>
          <aff>Creighton University School of Medicine</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Linda Herman declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sandeep Padala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Intisar Ahmed declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Khalid Bashir declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>31</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-17584.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">ACE inhibitors are medications used to treat and manage hypertension, which is a significant risk factor for coronary disease, heart failure, stroke, and a host of other cardiovascular conditions. Most cases are primary and not attributable to any specific etiology. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of ACE inhibitor therapy in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with hypertension and its related conditions and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of ACE inhibitors.</p></list-item><list-item><p>Summarize monitoring/follow-up for patients initiated on ACE inhibitor therapy.</p></list-item><list-item><p>Review the dosing parameters adjusting or replacing ACE inhibitor therapy based on adverse events or inadequate therapeutic response.</p></list-item><list-item><p>Explain the importance of ACE inhibitor therapy in hypertension management and how it affects therapeutic strategy as it pertains to improving care coordination and communication among the interprofessional team when using these agents to achieve therapeutic outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17584&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17584">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-17584.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Angiotensin-converting enzyme inhibitors (ACEIs) are the most commonly indicated medications in the treatment of cardiovascular and renal diseases, including heart failure, acute coronary syndrome, nephrotic syndrome, diabetes, and hypertension.<xref ref-type="bibr" rid="article-17584.r1">[1]</xref></p>
        <p>
<bold>Hypertension</bold>
</p>
        <p>Angiotensin-converting enzyme inhibitors effectively lower the mean arterial blood pressure as well as systolic and diastolic blood pressure both in hypertensive and normotensive subjects.<xref ref-type="bibr" rid="article-17584.r2">[2]</xref><xref ref-type="bibr" rid="article-17584.r3">[3]</xref>&#x000a0;Angiotensin-converting enzyme inhibitors have been evaluated as antihypertensive drugs in multiple randomized controlled trials.<xref ref-type="bibr" rid="article-17584.r4">[4]</xref>&#x000a0;In 2014, the Eighth Joint National Commission (JNC8) published evidence-based guidelines for treating high blood pressure in adults, which recommended that ACE inhibitors are one of four drug classes recommended for initial therapy for adults with elevated blood pressure.<xref ref-type="bibr" rid="article-17584.r5">[5]</xref>&#x000a0;The other three classes of drugs are calcium channel blockers, thiazide diuretics, and angiotensin receptor blockers, which are useful as initial therapy for the general nonblack population. Only thiazide and calcium channel blockers are recommended as initial therapy for the general black population with elevated blood pressure.<xref ref-type="bibr" rid="article-17584.r6">[6]</xref>&#x000a0;Recent guidelines released by the American Heart Association/American College of Cardiology (AHA/ACC) and the European Society of Cardiology (ESC) also recommend ACE inhibitors as first-line antihypertensive therapy, especially in patients with diabetes mellitus and cardiovascular diseases.<xref ref-type="bibr" rid="article-17584.r7">[7]</xref><xref ref-type="bibr" rid="article-17584.r8">[8]</xref>&#x000a0;Although ACE inhibitors are generally very effective antihypertensive drugs, they have been proven to be less effective in hypertensive Black race individuals than in whites in clinical practice.<xref ref-type="bibr" rid="article-17584.r9">[9]</xref></p>
        <p>
<bold>Heart Failure</bold>
</p>
        <p>Angiotensin-converting enzyme inhibitors (ACEIs) improve heart failure by decreasing afterload, preload, and systolic wall stress, which results in increased cardiac output without any increase in heart rate.<xref ref-type="bibr" rid="article-17584.r10">[10]</xref><xref ref-type="bibr" rid="article-17584.r11">[11]</xref>&#x000a0;ACE inhibitors play an important role in promoting salt excretion by augmenting the renal blood flow and reducing aldosterone and antidiuretic hormone production. Apart from decreasing the afterload, ACEIs also reduce cardiac myocyte hypertrophy. Since the 1980s, several large, prospective, randomized, placebo-controlled trials have proved that treatment with ACE inhibitors reduces overall mortality, especially in patients with heart failure with reduced ejection fraction (0HFrEF).<xref ref-type="bibr" rid="article-17584.r12">[12]</xref><xref ref-type="bibr" rid="article-17584.r13">[13]</xref><xref ref-type="bibr" rid="article-17584.r14">[14]</xref>&#x000a0;These trials demonstrated that ACE inhibitors reduce mortality even in asymptomatic patients with left ventricular dysfunction.<xref ref-type="bibr" rid="article-17584.r15">[15]</xref>&#x000a0;Based on the above-mentioned evidence, ACE inhibitors are strongly recommended as first-choice therapy in patients with heart failure.<xref ref-type="bibr" rid="article-17584.r16">[16]</xref><xref ref-type="bibr" rid="article-17584.r17">[17]</xref></p>
        <p>
<bold>Post Myocardial Infarction</bold>
</p>
        <p>Over the last few decades, several prospective, randomized trials have studied the effect of ACE inhibitors on mortality after myocardial infarction (MI).<xref ref-type="bibr" rid="article-17584.r18">[18]</xref><xref ref-type="bibr" rid="article-17584.r19">[19]</xref>&#x000a0;The vast majority of these trials have shown a significant decrease in mortality and a slowing of the progression to congestive heart failure after MI in patients treated with ACE inhibitors.<xref ref-type="bibr" rid="article-17584.r20">[20]</xref>&#x000a0;The clinical practice guidelines in the contemporary era recommend that patients with left ventricular dysfunction or heart failure be treated with ACE inhibitors without delay after infarction. It is also recommended that all patients should be treated with ACE inhibitors initially, with a review of the need for continuation later based on left ventricular function assessment.<xref ref-type="bibr" rid="article-17584.r21">[21]</xref></p>
        <p>
<bold>Diabetes</bold>
</p>
        <p>The Renin-Angiotensin-Aldosterone system and increased glomerular capillary pressure have been reported to increase the progression of renal dysfunction due to diabetes mellitus related nephropathy.<xref ref-type="bibr" rid="article-17584.r22">[22]</xref>&#x000a0;A large, prospective, randomized, placebo-controlled has demonstrated that ACE inhibitors slow down the progression of nephropathy in patients with insulin-dependent diabetes mellitus and significantly reduce the combined endpoints of dialysis, transplantation, and death.<xref ref-type="bibr" rid="article-17584.r23">[23]</xref>&#x000a0;Current recommendations are using ACEi or ARB as first-line therapy for hypertension in patients with a history of diabetes. Also, the use of ACEi in diabetic hypertensive patients with no history of coronary heart disease has been shown to decrease the incidence of myocardial infarction and improve heart function.<xref ref-type="bibr" rid="article-17584.r24">[24]</xref></p>
        <p>
<bold>Nephrotic Syndrome or Proteinuria</bold>
</p>
        <p>Angiotensin-converting enzyme inhibitors have been reported to decrease glomerular capillary pressure by decreasing arterial pressure and selectively dilating efferent arterioles.<xref ref-type="bibr" rid="article-17584.r25">[25]</xref>&#x000a0;It has been shown that the use of ACE inhibitors prevents the progression of microalbuminuria to overt proteinuria.<xref ref-type="bibr" rid="article-17584.r26">[26]</xref>&#x000a0;Angiotensin-converting enzyme inhibition provides long-term protection against the development and progression of proteinuria and stabilizes renal function in previously untreated patients with impaired renal function.<xref ref-type="bibr" rid="article-17584.r26">[26]</xref></p>
        <p>
<bold>Chronic Kidney Disease</bold>
</p>
        <p>ACE inhibitors or ARBs are the first-line drugs in managing chronic kidney disease (CKD) patients. The use of ACEI or ARB has been proven to have a superior effect compared to placebo treatment on decreasing proteinuria and slowing kidney disease progression. The efficacy of ACEI and ARB is comparable.<xref ref-type="bibr" rid="article-17584.r27">[27]</xref></p>
        <p><bold>Glomerular Disease and Post-transplant Glomerulonephritis</bold>\</p>
        <p>The use of ACE inhibitors or ARB is the mainstay of treatment in patients with glomerular diseases. It slows down the decline in glomerular filtration rate (GFR) and proteinuria.<xref ref-type="bibr" rid="article-17584.r28">[28]</xref>&#x000a0;The use of&#x000a0;renin-angiotensin-aldosterone inhibitors&#x000a0;prolongs graft survival in patients with post-transplant glomerulonephritis.<xref ref-type="bibr" rid="article-17584.r29">[29]</xref></p>
      </sec>
      <sec id="article-17584.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Angiotensin II causes direct vasoconstriction of precapillary arterioles and postcapillary venules, inhibits the reuptake of norepinephrine, stimulates the release of catecholamines from the adrenal medulla, reduces urinary excretion of sodium and water, stimulates synthesis and release of aldosterone, and stimulates hypertrophy of both vascular smooth muscle cells and cardiac myocytes.<xref ref-type="bibr" rid="article-17584.r30">[30]</xref><xref ref-type="bibr" rid="article-17584.r31">[31]</xref>&#x000a0;</p>
        <p>The exact mechanism of ACE inhibitors is not fully known. They interfere with the renin-angiotensin-aldosterone system, but their effect is not directly related to renin levels in the blood. As the name implies, ACE inhibitors block an angiotensin-converting enzyme that converts angiotensin I to angiotensin II. Decreased production of angiotensin II enhances natriuresis, lowers blood pressure, and prevents remodeling of smooth muscle and cardiac myocytes. Lowered arterial and venous pressure reduces preload and afterload. &#x000a0;Also, the hypothesis is that ACE inhibitors interfere with the degradation of bradykinin, a peptide that causes vasodilation.<xref ref-type="bibr" rid="article-17584.r32">[32]</xref></p>
        <p>Angiotensin-converting enzyme regulates the balance between the vasodilatory and natriuretic properties of bradykinin and the vasoconstrictive and salt-retentive properties of Angiotensin II. ACE inhibitors alter this balance by decreasing the formation of Angiotensin II and the degradation of bradykinin. ACE inhibitors also alter the formation and degradation of several other vasoactive substances, such as substance P,&#x000a0;but the contribution of these compounds to the therapeutic or adverse effects of ACE inhibitors is uncertain.<xref ref-type="bibr" rid="article-17584.r33">[33]</xref></p>
      </sec>
      <sec id="article-17584.s4" sec-type="Administration">
        <title>Administration</title>
        <p>ACE inhibitors differ in their chemical structure, potency, bioavailability, plasma half-life, route of elimination, as well as their distribution and affinity for tissue-bound&#x000a0;angiotensin-converting-enzyme.</p>
        <p>Depending on the chemical structure, ACE inhibitors are classified into three groups.<xref ref-type="bibr" rid="article-17584.r34">[34]</xref><xref ref-type="bibr" rid="article-17584.r35">[35]</xref></p>
        <p>Sulfhydryl-containing ACE inhibitors</p>
        <list list-type="bullet">
          <list-item>
            <p>Captopril &#x02013;&#x000a0;Hypertension therapy is 25 mg, either BID or TID, with a maximum of 450 mg. Heart failure therapy is 6.25 mg TID, with a maximum of 450 mg.</p>
          </list-item>
        </list>
        <p>Dicarboxylic-containing ACE inhibitors: see table.</p>
        <p>Phosphorus-containing ACE inhibitor.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Fosinopril &#x02013;&#x000a0;Hypertension therapy dosing is 10 mg, increasing to a maximum dose of 80 mg. May split into two equal doses during the day to control blood pressure. Heart failure therapy is 5 to 10 mg daily to a maximum dose of 40 mg.</p>
          </list-item>
        </list>
        <p>
<bold>General Dosing Information</bold>
</p>
        <p>All of the ACE inhibitors are prescribed orally, except for enalapril, which can be given intravenously. Enalapril's IV dosage is&#x000a0;initially 0.625 to 1.25 mg every 6 hours. Dosage titration up can be to 5 mg IV every 6 hours. Geriatric dosing should definitely initiate at the lower end of the adult dosing regimen.</p>
        <p>There should be a dosage decrease in patients with heart failure, salt-depleted patients, and/or renal impairment.&#x000a0;</p>
        <p>Lisinopril and captopril are the only ACE inhibitors that do not have to be activated in the body to be effective. All the other ACE inhibitors are prodrugs and require activation. Most reach peak serum levels within 1 hour after ingestion. Since most of the activation occurs in the liver, a non-prodrug form is preferable in patients with underlying liver issues.<xref ref-type="bibr" rid="article-17584.r36">[36]</xref></p>
      </sec>
      <sec id="article-17584.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>About 1 to 10% will develop a dry, nonproductive paroxysmal cough, and there is no treatment for the cough.<xref ref-type="bibr" rid="article-17584.r37">[37]</xref><xref ref-type="bibr" rid="article-17584.r38">[38]</xref>&#x000a0;Experimental studies have shown that using non-steroidal anti-inflammatory agents (NSAIDs) and intermediate-dose aspirin (500 mg) can help with ACE inhibitors induced cough.<xref ref-type="bibr" rid="article-17584.r39">[39]</xref>&#x000a0;ACE inhibitor-induced cough is reported more frequently among women than men.<xref ref-type="bibr" rid="article-17584.r40">[40]</xref>&#x000a0;The cough is usually dry, and it often requires cessation of therapy.</p>
        <p>Angioedema is the most significant adverse effect of ACEi. It can&#x000a0;affect&#x000a0;any part of the body, including the intestine, but the most concerning is edema of the tongue, glottis, and/or larynx, causing airway obstruction.<xref ref-type="bibr" rid="article-17584.r41">[41]</xref>&#x000a0;Angioedema has a higher rate of incidence in the African-American population. When airway compromise is present, the treatment always secures the airway with an endotracheal tube that allows ventilation until the edema resolves. Multiple treatments have been tried, such as diphenhydramine, methylprednisolone, and epinephrine. Also, fresh frozen plasma and the newer agents, bradykinin blocking agents, have been tried. There are case reports that these bradykinin blocking agents might improve angioedema, but no literature exists proving that they are better than the other agents.<xref ref-type="bibr" rid="article-17584.r42">[42]</xref>&#x000a0;There is an ongoing phase III trial&#x000a0;at this time.</p>
        <p>Life-threatening anaphylactoid reactions have occurred in patients receiving Hymenoptera venom desensitization treatment and patients receiving dialysis with high-flux membranes. Treatment includes diphenhydramine, epinephrine, and blood pressure support with fluids and catecholamines.<xref ref-type="bibr" rid="article-17584.r43">[43]</xref><xref ref-type="bibr" rid="article-17584.r44">[44]</xref></p>
        <p>Angiotensin-converting enzyme inhibitors have been reported to cause a reversible decline in renal function. Those with heart failure who depend on the renin-angiotensin-aldosterone system may develop changes in renal function with the use of ACE inhibitors.<xref ref-type="bibr" rid="article-17584.r45">[45]</xref>&#x000a0;Also, about one-fifth of the patients with renal artery stenosis develop increases in blood urea nitrogen and creatinine.<xref ref-type="bibr" rid="article-17584.r46">[46]</xref>&#x000a0;Any patient who already has a renal insufficiency is susceptible to a worsening of renal function. The renal function requires monitoring during treatment for susceptible groups.<xref ref-type="bibr" rid="article-17584.r47">[47]</xref></p>
        <p>As with any medication that lowers blood pressure, hypotension is an adverse reaction. Those at risk for this side effect: heart failure with systolic blood pressure below 100 mmHg, ischemic heart disease, cerebrovascular disease, hyponatremia, high dose diuretic therapy, renal dialysis, or severe volume and/or sodium depletion.<xref ref-type="bibr" rid="article-17584.r48">[48]</xref></p>
        <p>ACE inhibitors may cause hyperkalemia. Those at risk for this side effect: prior history of renal impairment and/or diabetes, simultaneous use of potassium-sparing diuretics, and/or potassium&#x000a0;supplements.<xref ref-type="bibr" rid="article-17584.r49">[49]</xref>&#x000a0;Treatment depends upon the potassium level, EKG changes, and whether the patient still has kidney function and produces urine.<xref ref-type="bibr" rid="article-17584.r47">[47]</xref>&#x000a0;There has been one report of increased sudden death in patients taking ACE inhibitors and co-trimoxazole simultaneously. The mechanism is believed to be hyperkalemia.<xref ref-type="bibr" rid="article-17584.r50">[50]</xref></p>
        <p>Cholestatic jaundice or hepatitis is another rare but serious adverse effect that can progress to hepatic necrosis and sometimes death. The clinician needs to discontinue the drug, and the patient managed appropriately.<xref ref-type="bibr" rid="article-17584.r51">[51]</xref></p>
      </sec>
      <sec id="article-17584.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>ACE inhibitors are contraindicated in patients with a history of angioedema or hypersensitivity related to treatment with an ACE inhibitor and those with hereditary or idiopathic angioedema.<xref ref-type="bibr" rid="article-17584.r52">[52]</xref>&#x000a0;</p>
        <p>These drugs should not be given to patients already taking a direct renin inhibitor such as aliskiren.</p>
        <p>ACE inhibitors should not be given during pregnancy.&#x000a0;They were&#x000a0;Category D in pregnancy under the old FDA system because it is known to cause skull hypoplasia, anuria, hypotension, renal failure, lung hypoplasia, skeletal deformations, oligohydramnios, and death.<xref ref-type="bibr" rid="article-17584.r53">[53]</xref></p>
        <p>The combination therapy&#x000a0;of ACEi and ARBs&#x000a0;does not reduce mortality in patients with heart failure compared to monotherapy. In fact, the combination therapy can worsen renal indices and cause life-threatening hyperkalemia.<xref ref-type="bibr" rid="article-17584.r54">[54]</xref></p>
      </sec>
      <sec id="article-17584.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Renal function and electrolytes need to be checked regularly due to the effects of the drug on the renin-angiotensin-aldosterone system.&#x000a0; For patients with increasing potassium, drop-in GFR, or increasing creatinine, the drug needs to be adjusted accordingly or discontinued.<xref ref-type="bibr" rid="article-17584.r55">[55]</xref></p>
      </sec>
      <sec id="article-17584.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Excessive doses of ACE inhibitors are usually well-tolerated, but they can cause hypotension, drop-in GFR, and electrolyte derangements. In addition, since&#x000a0;ACE inhibitors block aldosterone, they can cause hyperkalemia and hyponatremia.<xref ref-type="bibr" rid="article-17584.r56">[56]</xref><xref ref-type="bibr" rid="article-17584.r57">[57]</xref></p>
        <p>If the patient presents within 1 hour of ingestion and is awake and able to protect their airway, activated charcoal can be given. If they remain asymptomatic for 6 hours of observation, they can be considered medically stable for either discharge or referral to psychiatry.<xref ref-type="bibr" rid="article-17584.r58">[58]</xref></p>
        <p>For those with hypotension, fluids should be the first line of therapy. There is no antidote for ACE inhibitor poisoning. Naloxone has been used in captopril overdoses in the past with some success and can be a choice if intravenous fluids are not successful. Also, vasopressors are an option for the treatment of hypotension.<xref ref-type="bibr" rid="article-17584.r59">[59]</xref></p>
      </sec>
      <sec id="article-17584.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>ACE inhibitors are one of the most widely used drugs for hypertension and heart failure, but their popularity does not mean they do not&#x000a0;require the management of an interprofessional team. Besides nephrologists and cardiologists, these drugs are widely prescribed by nurse practitioners and primary care providers. While ACE inhibitors are relatively safe, a pharmacist should examine the patient's medication record to verify dosing and check for drug-drug interactions. Nursing can provide patient counsel, monitor for interactions and adverse events, and report any issues to the prescriber. It is important to monitor renal function and levels of electrolytes regularly.<xref ref-type="bibr" rid="article-17584.r60">[60]</xref>&#x000a0;Because many ACE inhibitors are currently available, it is important to keep up with the guidelines and recommendations, and the pharmacist can help the prescriber in this area.<xref ref-type="bibr" rid="article-17584.r61">[61]</xref>&#x000a0;An interprofessional team approach will optimize ACE inhibitor therapy resulting in improved patient outcomes. [Level 5]</p>
      </sec>
      <sec id="article-17584.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=17584&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=17584">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/17584/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=17584">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-17584.s11">
        <fig id="article-17584.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Dicarboxyl-containing ACE inhibitors and doses Contributed by Linda L Herman</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ACE__Inhibitors__dosing" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-17584.s12">
        <title>References</title>
        <ref id="article-17584.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasution</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>The use of ACE inhibitor in cardiovascular disease.</article-title>
            <source>Acta Med Indones</source>
            <year>2006</year>
            <season>Jan-Mar</season>
            <volume>38</volume>
            <issue>1</issue>
            <fpage>60</fpage>
            <page-range>60-4</page-range>
            <pub-id pub-id-type="pmid">16479034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vidt</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Bravo</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Fouad</surname>
                <given-names>FM</given-names>
              </name>
            </person-group>
            <article-title>Drug therapy. Captopril.</article-title>
            <source>N Engl J Med</source>
            <year>1982</year>
            <month>Jan</month>
            <day>28</day>
            <volume>306</volume>
            <issue>4</issue>
            <fpage>214</fpage>
            <page-range>214-9</page-range>
            <pub-id pub-id-type="pmid">7033784</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Todd</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Heel</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.</article-title>
            <source>Drugs</source>
            <year>1986</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>3</issue>
            <fpage>198</fpage>
            <page-range>198-248</page-range>
            <pub-id pub-id-type="pmid">3011386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Messerli</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>Bangalore</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bavishi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rimoldi</surname>
                <given-names>SF</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or&#x000a0;Not&#x000a0;to Use?</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>Apr</month>
            <day>03</day>
            <volume>71</volume>
            <issue>13</issue>
            <fpage>1474</fpage>
            <page-range>1474-1482</page-range>
            <pub-id pub-id-type="pmid">29598869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Oparil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Cushman</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Dennison-Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Handler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>LeFevre</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>MacKenzie</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Ogedegbe</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Svetkey</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Narva</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Ortiz</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).</article-title>
            <source>JAMA</source>
            <year>2014</year>
            <month>Feb</month>
            <day>05</day>
            <volume>311</volume>
            <issue>5</issue>
            <fpage>507</fpage>
            <page-range>507-20</page-range>
            <pub-id pub-id-type="pmid">24352797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>The JNC 8 hypertension guidelines: an in-depth guide.</article-title>
            <source>Am J Manag Care</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1 Spec No.</issue>
            <fpage>E8</fpage>
            <pub-id pub-id-type="pmid">25618230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whelton</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Carey</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Aronow</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Collins</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Dennison Himmelfarb</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>DePalma</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Gidding</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jamerson</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>MacLaughlin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Muntner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ovbiagele</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Spencer</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Stafford</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Taler</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Wright</surname>
                <given-names>JT</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2018</year>
            <month>May</month>
            <day>15</day>
            <volume>71</volume>
            <issue>19</issue>
            <fpage>e127</fpage>
            <page-range>e127-e248</page-range>
            <pub-id pub-id-type="pmid">29146535</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mancia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Spiering</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Agabiti Rosei</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Azizi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Burnier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clement</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Coca</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Simone</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dominiczak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kahan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mahfoud</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Redon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zanchetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kerins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kreutz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Laurent</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lip</surname>
                <given-names>GYH</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Narkiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schmieder</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Shlyakhto</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tsioufis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Aboyans</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Desormais</surname>
                <given-names>I</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2018 ESC/ESH Guidelines for the management of arterial hypertension.</article-title>
            <source>Eur Heart J</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>39</volume>
            <issue>33</issue>
            <fpage>3021</fpage>
            <page-range>3021-3104</page-range>
            <pub-id pub-id-type="pmid">30165516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <collab>Veterans Administration Co-Operative Study Group on Antihypertensive Agents</collab>
            <article-title>Racial differences in response to low-dose captopril are abolished by the addition of hydrochlorothiazide.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>1982</year>
            <volume>14 Suppl 2</volume>
            <issue>Suppl 2</issue>
            <fpage>97S</fpage>
            <page-range>97S-101S</page-range>
            <pub-id pub-id-type="pmid">6753911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gavras</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Faxon</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Berkoben</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Brunner</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>TJ</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin converting enzyme inhibition in patients with congestive heart failure.</article-title>
            <source>Circulation</source>
            <year>1978</year>
            <month>Nov</month>
            <volume>58</volume>
            <issue>5</issue>
            <fpage>770</fpage>
            <page-range>770-6</page-range>
            <pub-id pub-id-type="pmid">699246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dzau</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Colucci</surname>
                <given-names>WS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Curfman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Meggs</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hollenberg</surname>
                <given-names>NK</given-names>
              </name>
            </person-group>
            <article-title>Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>1980</year>
            <month>Jun</month>
            <day>19</day>
            <volume>302</volume>
            <issue>25</issue>
            <fpage>1373</fpage>
            <page-range>1373-9</page-range>
            <pub-id pub-id-type="pmid">6246425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <collab>CONSENSUS Trial Study Group</collab>
            <article-title>Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).</article-title>
            <source>N Engl J Med</source>
            <year>1987</year>
            <month>Jun</month>
            <day>04</day>
            <volume>316</volume>
            <issue>23</issue>
            <fpage>1429</fpage>
            <page-range>1429-35</page-range>
            <pub-id pub-id-type="pmid">2883575</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <collab>SOLVD Investigators</collab>
              <name>
                <surname>Yusuf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pitt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Hood</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Cohn</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.</article-title>
            <source>N Engl J Med</source>
            <year>1991</year>
            <month>Aug</month>
            <day>01</day>
            <volume>325</volume>
            <issue>5</issue>
            <fpage>293</fpage>
            <page-range>293-302</page-range>
            <pub-id pub-id-type="pmid">2057034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <article-title>Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.</article-title>
            <source>Lancet</source>
            <year>1993</year>
            <month>Oct</month>
            <day>02</day>
            <volume>342</volume>
            <issue>8875</issue>
            <fpage>821</fpage>
            <page-range>821-8</page-range>
            <pub-id pub-id-type="pmid">8104270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Braunwald</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Moy&#x000e9;</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Basta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Cuddy</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Geltman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Goldman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Flaker</surname>
                <given-names>GC</given-names>
              </name>
            </person-group>
            <article-title>Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Sep</month>
            <day>03</day>
            <volume>327</volume>
            <issue>10</issue>
            <fpage>669</fpage>
            <page-range>669-77</page-range>
            <pub-id pub-id-type="pmid">1386652</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bozkurt</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Colvin</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Drazner</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Fonarow</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Givertz</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hollenberg</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lindenfeld</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Masoudi</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>McBride</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Westlake</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.</article-title>
            <source>Circulation</source>
            <year>2017</year>
            <month>Aug</month>
            <day>08</day>
            <volume>136</volume>
            <issue>6</issue>
            <fpage>e137</fpage>
            <page-range>e137-e161</page-range>
            <pub-id pub-id-type="pmid">28455343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Voors</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cleland</surname>
                <given-names>JGF</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gonz&#x000e1;lez-Juanatey</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Harjola</surname>
                <given-names>VP</given-names>
              </name>
              <name>
                <surname>Jankowska</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nihoyannopoulos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Parissis</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Pieske</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Riley</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Ruilope</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Ruschitzka</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rutten</surname>
                <given-names>FH</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>P</given-names>
              </name>
              <collab>ESC Scientific Document Group</collab>
            </person-group>
            <article-title>2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.</article-title>
            <source>Eur Heart J</source>
            <year>2016</year>
            <month>Jul</month>
            <day>14</day>
            <volume>37</volume>
            <issue>27</issue>
            <fpage>2129</fpage>
            <page-range>2129-2200</page-range>
            <pub-id pub-id-type="pmid">27206819</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Swedberg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Held</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kjekshus</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rasmussen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ryd&#x000e9;n</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wedel</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II).</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Sep</month>
            <day>03</day>
            <volume>327</volume>
            <issue>10</issue>
            <fpage>678</fpage>
            <page-range>678-84</page-range>
            <pub-id pub-id-type="pmid">1495520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambrosioni</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Borghi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Magnani</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Jan</month>
            <day>12</day>
            <volume>332</volume>
            <issue>2</issue>
            <fpage>80</fpage>
            <page-range>80-5</page-range>
            <pub-id pub-id-type="pmid">7990904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfeffer</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Left ventricular remodeling after acute myocardial infarction.</article-title>
            <source>Annu Rev Med</source>
            <year>1995</year>
            <volume>46</volume>
            <fpage>455</fpage>
            <page-range>455-66</page-range>
            <pub-id pub-id-type="pmid">7598478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Gara</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ascheim</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Casey</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>de Lemos</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Ettinger</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Fang</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Fesmire</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Franklin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Krumholz</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Linderbaum</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Morrow</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Newby</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ornato</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ou</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Radford</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Tamis-Holland</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Tommaso</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Tracy</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>DX</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Jacobs</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Brindis</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Creager</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>DeMets</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guyton</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Hochman</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Kovacs</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Kushner</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Ohman</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Yancy</surname>
                <given-names>CW</given-names>
              </name>
              <collab>American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</collab>
            </person-group>
            <article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</article-title>
            <source>Circulation</source>
            <year>2013</year>
            <month>Jan</month>
            <day>29</day>
            <volume>127</volume>
            <issue>4</issue>
            <fpage>e362</fpage>
            <page-range>e362-425</page-range>
            <pub-id pub-id-type="pmid">23247304</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ichikawa</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Glomerular actions of angiotensin II.</article-title>
            <source>Am J Med</source>
            <year>1984</year>
            <month>May</month>
            <day>31</day>
            <volume>76</volume>
            <issue>5B</issue>
            <fpage>43</fpage>
            <page-range>43-9</page-range>
            <pub-id pub-id-type="pmid">6203406</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Hunsicker</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Bain</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Rohde</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.</article-title>
            <source>N Engl J Med</source>
            <year>1993</year>
            <month>Nov</month>
            <day>11</day>
            <volume>329</volume>
            <issue>20</issue>
            <fpage>1456</fpage>
            <page-range>1456-62</page-range>
            <pub-id pub-id-type="pmid">8413456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hua</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Real-world use of ACEI/ARB in diabetic hypertensive patients before the initial diagnosis of obstructive coronary artery disease: patient characteristics and&#x000a0;long-term follow-up outcome.</article-title>
            <source>J Transl Med</source>
            <year>2020</year>
            <month>Apr</month>
            <day>01</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>150</fpage>
            <pub-id pub-id-type="pmid">32238168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anderson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rennke</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat.</article-title>
            <source>J Clin Invest</source>
            <year>1986</year>
            <month>Jun</month>
            <volume>77</volume>
            <issue>6</issue>
            <fpage>1993</fpage>
            <page-range>1993-2000</page-range>
            <pub-id pub-id-type="pmid">3011863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rachmani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lishner</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study.</article-title>
            <source>Arch Intern Med</source>
            <year>1996</year>
            <month>Feb</month>
            <day>12</day>
            <volume>156</volume>
            <issue>3</issue>
            <fpage>286</fpage>
            <page-range>286-9</page-range>
            <pub-id pub-id-type="pmid">8572838</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silvari&#x000f1;o</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rios</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baldovinos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Chichet</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Perg</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sola</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Saona</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>De Souza</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lamadrid</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Gadola</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Is Chronic Kidney Disease Progression Influenced by the Type of Renin-Angiotensin-System Blocker Used?</article-title>
            <source>Nephron</source>
            <year>2019</year>
            <volume>143</volume>
            <issue>2</issue>
            <fpage>100</fpage>
            <page-range>100-107</page-range>
            <pub-id pub-id-type="pmid">31203280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rigat</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hubert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Alhenc-Gelas</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cambien</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corvol</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Soubrier</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.</article-title>
            <source>J Clin Invest</source>
            <year>1990</year>
            <month>Oct</month>
            <volume>86</volume>
            <issue>4</issue>
            <fpage>1343</fpage>
            <page-range>1343-6</page-range>
            <pub-id pub-id-type="pmid">1976655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pazik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ostrowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lewandowski</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Mr&#x000f3;z</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Perkowska-Ptasi&#x00144;ska</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baczkowska</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Durlik</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Renin-Angiotensin-Aldosterone system inhibitors and statins prolong graft survival in post-transplant glomerulonephritis.</article-title>
            <source>Ann Transplant</source>
            <year>2008</year>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>41</fpage>
            <page-range>41-5</page-range>
            <pub-id pub-id-type="pmid">19034222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FOLKOW</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>JOHANSSON</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>MELLANDER</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The comparative effects of angiotensin and noradrenaline on consecutive vascular sections.</article-title>
            <source>Acta Physiol Scand</source>
            <year>1961</year>
            <month>Oct</month>
            <volume>53</volume>
            <fpage>99</fpage>
            <page-range>99-104</page-range>
            <pub-id pub-id-type="pmid">13893844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bell</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Madri</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>Influence of the angiotensin system on endothelial and smooth muscle cell migration.</article-title>
            <source>Am J Pathol</source>
            <year>1990</year>
            <month>Jul</month>
            <volume>137</volume>
            <issue>1</issue>
            <fpage>7</fpage>
            <page-range>7-12</page-range>
            <pub-id pub-id-type="pmid">2164777</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Timmermans</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Chiu</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Herblin</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Benfield</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Carini</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Wexler</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Saye</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin II receptors and angiotensin II receptor antagonists.</article-title>
            <source>Pharmacol Rev</source>
            <year>1993</year>
            <month>Jun</month>
            <volume>45</volume>
            <issue>2</issue>
            <fpage>205</fpage>
            <page-range>205-51</page-range>
            <pub-id pub-id-type="pmid">8372104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cascieri</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Bull</surname>
                <given-names>HG</given-names>
              </name>
              <name>
                <surname>Mumford</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Patchett</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Thornberry</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422.</article-title>
            <source>Mol Pharmacol</source>
            <year>1984</year>
            <month>Mar</month>
            <volume>25</volume>
            <issue>2</issue>
            <fpage>287</fpage>
            <page-range>287-93</page-range>
            <pub-id pub-id-type="pmid">6199659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spyroulias</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Galanis</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Pairas</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manessi-Zoupa</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cordopatis</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Structural features of angiotensin-I converting enzyme catalytic sites: conformational studies in solution, homology models and comparison with other zinc metallopeptidases.</article-title>
            <source>Curr Top Med Chem</source>
            <year>2004</year>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>403</fpage>
            <page-range>403-29</page-range>
            <pub-id pub-id-type="pmid">14965309</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Regulski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Regulska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Stanisz</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Murias</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gieremek</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wzgarda</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Niznik</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Chemistry and pharmacology of Angiotensin-converting enzyme inhibitors.</article-title>
            <source>Curr Pharm Des</source>
            <year>2015</year>
            <volume>21</volume>
            <issue>13</issue>
            <fpage>1764</fpage>
            <page-range>1764-75</page-range>
            <pub-id pub-id-type="pmid">25388457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williams</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Drug discovery in renin-angiotensin system intervention: past and future.</article-title>
            <source>Ther Adv Cardiovasc Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>118</fpage>
            <page-range>118-25</page-range>
            <pub-id pub-id-type="pmid">27126389</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinargote</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Guillen</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Guarderas</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitors: upper respiratory symptoms.</article-title>
            <source>BMJ Case Rep</source>
            <year>2014</year>
            <month>Jul</month>
            <day>17</day>
            <volume>2014</volume>
            <pub-id pub-id-type="pmid">25035451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Israili</surname>
                <given-names>ZH</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>WD</given-names>
              </name>
            </person-group>
            <article-title>Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology.</article-title>
            <source>Ann Intern Med</source>
            <year>1992</year>
            <month>Aug</month>
            <day>01</day>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-42</page-range>
            <pub-id pub-id-type="pmid">1616218</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tenenbaum</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shemesh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisman</surname>
                <given-names>EZ</given-names>
              </name>
              <name>
                <surname>Nosrati</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Motro</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intermediate but not low doses of aspirin can suppress angiotensin-converting enzyme inhibitor-induced cough.</article-title>
            <source>Am J Hypertens</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>776</fpage>
            <page-range>776-82</page-range>
            <pub-id pub-id-type="pmid">10933569</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Os</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bratland</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dahl&#x000f6;f</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gisholt</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Syvertsen</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Tretli</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Female sex as an important determinant of lisinopril-induced cough.</article-title>
            <source>Lancet</source>
            <year>1992</year>
            <month>Feb</month>
            <day>08</day>
            <volume>339</volume>
            <issue>8789</issue>
            <fpage>372</fpage>
            <pub-id pub-id-type="pmid">1346451</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Slater</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Merrill</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Guess</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Roylance</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Inman</surname>
                <given-names>WH</given-names>
              </name>
              <name>
                <surname>Ewan</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Clinical profile of angioedema associated with angiotensin converting-enzyme inhibition.</article-title>
            <source>JAMA</source>
            <year>1988</year>
            <month>Aug</month>
            <day>19</day>
            <volume>260</volume>
            <issue>7</issue>
            <fpage>967</fpage>
            <page-range>967-70</page-range>
            <pub-id pub-id-type="pmid">2840522</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Korzeniowska</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cielewiczi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pawlaczyk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Motowidlo</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Andrys-Wawrzyniak</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Jablecka</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>ANGIOEDEMA AFTER ANGIOTENSIN-CONVERTING ENZYME INHIBITORS.</article-title>
            <source>Acta Pol Pharm</source>
            <year>2017</year>
            <month>May</month>
            <volume>74</volume>
            <issue>3</issue>
            <fpage>983</fpage>
            <page-range>983-986</page-range>
            <pub-id pub-id-type="pmid">29513968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tunon-de-Lara</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Villanueva</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marcos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Taytard</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitors and anaphylactoid reactions during venom immunotherapy.</article-title>
            <source>Lancet</source>
            <year>1992</year>
            <month>Oct</month>
            <day>10</day>
            <volume>340</volume>
            <issue>8824</issue>
            <fpage>908</fpage>
            <pub-id pub-id-type="pmid">1357311</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rousaud Baron</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Camps</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Cubells</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Comamala</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>ACE inhibitors and anaphylactoid reactions to high-flux membrane dialysis (AN69): clinical aspects.</article-title>
            <source>Nephron</source>
            <year>1992</year>
            <volume>60</volume>
            <issue>4</issue>
            <fpage>487</fpage>
            <pub-id pub-id-type="pmid">1584327</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>BF</given-names>
              </name>
              <name>
                <surname>Whitworth</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kincaid-Smith</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Renal insufficiency with combinations of angiotensin converting enzyme inhibitors and diuretics.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1984</year>
            <month>Mar</month>
            <day>17</day>
            <volume>288</volume>
            <issue>6420</issue>
            <fpage>844</fpage>
            <page-range>844-5</page-range>
            <pub-id pub-id-type="pmid">6322905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khosla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Siddiqui</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benatar</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Salem</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Elbzour</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Vidyarthi</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lubell</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Safety of angiotensin-converting enzyme inhibitors in patients with bilateral renal artery stenosis following successful renal artery stent revascularization.</article-title>
            <source>Am J Ther</source>
            <year>2006</year>
            <season>Jul-Aug</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>306</fpage>
            <page-range>306-8</page-range>
            <pub-id pub-id-type="pmid">16858164</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosano</surname>
                <given-names>GMC</given-names>
              </name>
              <name>
                <surname>Tamargo</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kjeldsen</surname>
                <given-names>KP</given-names>
              </name>
              <name>
                <surname>Lainscak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Agewall</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>SD</given-names>
              </name>
              <name>
                <surname>Ceconi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Coats</surname>
                <given-names>AJS</given-names>
              </name>
              <name>
                <surname>Drexel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Filippatos</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kaski</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Lund</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Niessner</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ponikowski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Savarese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Schmidt</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Seferovic</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wassmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Walther</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>BS</given-names>
              </name>
            </person-group>
            <article-title>Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.</article-title>
            <source>Eur Heart J Cardiovasc Pharmacother</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>4</volume>
            <issue>3</issue>
            <fpage>180</fpage>
            <page-range>180-188</page-range>
            <pub-id pub-id-type="pmid">29726985</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hodsman</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Isles</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Usherwood</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Webb</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Robertson</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Factors related to first dose hypotensive effect of captopril: prediction and treatment.</article-title>
            <source>Br Med J (Clin Res Ed)</source>
            <year>1983</year>
            <month>Mar</month>
            <day>12</day>
            <volume>286</volume>
            <issue>6368</issue>
            <fpage>832</fpage>
            <page-range>832-4</page-range>
            <pub-id pub-id-type="pmid">6403103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burnakis</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Mioduch</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Combined therapy with captopril and potassium supplementation. A potential for hyperkalemia.</article-title>
            <source>Arch Intern Med</source>
            <year>1984</year>
            <month>Dec</month>
            <volume>144</volume>
            <issue>12</issue>
            <fpage>2371</fpage>
            <page-range>2371-2</page-range>
            <pub-id pub-id-type="pmid">6391404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perazella</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemia and trimethoprim-sulfamethoxazole: a new problem emerges 25 years later.</article-title>
            <source>Conn Med</source>
            <year>1997</year>
            <month>Aug</month>
            <volume>61</volume>
            <issue>8</issue>
            <fpage>451</fpage>
            <page-range>451-8</page-range>
            <pub-id pub-id-type="pmid">9309892</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rahmat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Winchester</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Schreiner</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Captopril-associated cholestatic jaundice.</article-title>
            <source>Ann Intern Med</source>
            <year>1985</year>
            <month>Jan</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>56</fpage>
            <page-range>56-8</page-range>
            <pub-id pub-id-type="pmid">3881069</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Snowden</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>60</volume>
            <issue>1</issue>
            <fpage>8</fpage>
            <page-range>8-13</page-range>
            <pub-id pub-id-type="pmid">8689816</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quan</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists.</article-title>
            <source>Early Hum Dev</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>82</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-8</page-range>
            <pub-id pub-id-type="pmid">16427219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuenzli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bucher</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Anand</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Arutiunov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kum</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>McKelvie</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Afzal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Nordmann</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure.</article-title>
            <source>PLoS One</source>
            <year>2010</year>
            <month>Apr</month>
            <day>01</day>
            <volume>5</volume>
            <issue>4</issue>
            <fpage>e9946</fpage>
            <pub-id pub-id-type="pmid">20376345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lucas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Christie</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Waring</surname>
                <given-names>WS</given-names>
              </name>
            </person-group>
            <article-title>Rapid onset of haemodynamic effects after angiotensin converting enzyme-inhibitor overdose: implications for initial patient triage.</article-title>
            <source>Emerg Med J</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>23</volume>
            <issue>11</issue>
            <fpage>854</fpage>
            <page-range>854-7</page-range>
            <pub-id pub-id-type="pmid">17057137</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sorodoc</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sorodoc</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lionte</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gazzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jaba</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>Mungiu</surname>
                <given-names>OC</given-names>
              </name>
            </person-group>
            <article-title>[Intentional poisoning with ACE inhibitors. Emergeny Hospital Ia&#x0015f;i].</article-title>
            <source>Rev Med Chir Soc Med Nat Iasi</source>
            <year>2010</year>
            <season>Apr-Jun</season>
            <volume>114</volume>
            <issue>2</issue>
            <fpage>359</fpage>
            <page-range>359-62</page-range>
            <pub-id pub-id-type="pmid">20700967</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varughese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>EB</given-names>
              </name>
            </person-group>
            <article-title>Consequences of angiotensin-converting enzyme inhibitor overdose.</article-title>
            <source>Am J Hypertens</source>
            <year>1989</year>
            <month>May</month>
            <volume>2</volume>
            <issue>5 Pt 1</issue>
            <fpage>355</fpage>
            <page-range>355-7</page-range>
            <pub-id pub-id-type="pmid">2541742</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jackson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Corke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Agar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Enalapril overdose treated with angiotensin infusion.</article-title>
            <source>Lancet</source>
            <year>1993</year>
            <month>Mar</month>
            <day>13</day>
            <volume>341</volume>
            <issue>8846</issue>
            <fpage>703</fpage>
            <pub-id pub-id-type="pmid">8095618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lip</surname>
                <given-names>GY</given-names>
              </name>
              <name>
                <surname>Ferner</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Poisoning with anti-hypertensive drugs: angiotensin converting enzyme inhibitors.</article-title>
            <source>J Hum Hypertens</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>711</fpage>
            <page-range>711-5</page-range>
            <pub-id pub-id-type="pmid">8551483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Vaughan</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Angiotensin-converting enzyme inhibitors.</article-title>
            <source>Circulation</source>
            <year>1998</year>
            <month>Apr</month>
            <day>14</day>
            <volume>97</volume>
            <issue>14</issue>
            <fpage>1411</fpage>
            <page-range>1411-20</page-range>
            <pub-id pub-id-type="pmid">9577953</pub-id>
          </element-citation>
        </ref>
        <ref id="article-17584.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pongpanich</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pitakpaiboonkul</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Takkavatakarn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Praditpornsilpa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Eiam-Ong</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Susantitaphong</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis.</article-title>
            <source>Int Urol Nephrol</source>
            <year>2018</year>
            <month>Dec</month>
            <volume>50</volume>
            <issue>12</issue>
            <fpage>2261</fpage>
            <page-range>2261-2278</page-range>
            <pub-id pub-id-type="pmid">30324578</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
